

*This press release contains forward-looking statements and you are cautioned not to place undue reliance on any forward-looking statements contained herein. We can give no assurance that these forward-looking statements will prove to have been correct. Expectations reflected in these forward-looking statements are subject to change and we undertake no obligation and do not intend to update or revise any forward-looking statements herein.*



中國抗體製藥有限公司

**SinoMab BioScience Limited**

(Stock Code : 3681.HK)

**Develop Platform with Comprehensive Industry Chain Allocation**

**Devoted to the Innovation of Therapeutics for the Treatment of Immunological Diseases**

**SinoMab BioScience Successfully Listed on Main Board of SEHK**

[29 November 2019, Hong Kong] **SinoMab BioScience Limited** (“**SinoMab BioScience**” or the “**Company**”, together with its subsidiaries, the “**Group**”; stock code: **3681.HK**), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, primarily mAb-based biologics, is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited (“**SEHK**”) on 12 November 2019.

SinoMab BioScience is one of a few select biopharmaceutical companies in the Greater China Region that has full-fledged capability. The Company has built a platform with an industry chain allocation to standardize and systemically monitor the Company’s R&D, clinical trials and manufacturing process. This comprehensive platform integrates all-industry functionalities, including target identification, drug candidate development, pre-clinical research, clinical trials, clinical production, quality control and quality assurance, regulatory approval and commercial-scale production up to the commercialization stage.

As of 22 October 2019, SinoMab BioScience has built up a product pipeline consisting of six drug candidates, including portfolio of first-in-target and first-in-class drug candidates. The most near-commercialization

candidate SM03 is clinically proven, first-in-target anti-CD22 mAb for the treatment of RA and potentially other immunological diseases. SM03 is currently in Phase III clinical trial for RA in China, and we aim to complete patient enrollment by the end of 2019.

**Dr. Shui On LEUNG, the Executive Director, Chairman of the Board and Chief Executive Officer of SinoMab BioScience Limited** said in the listing ceremony, “We are profoundly honored to be the first local Hong Kong-based biopharmaceutical company listed on the Main Board of SEHK. Today, SinoMab BioScience officially entered the Hong Kong stock market and tapped into the international capital market, marking an important milestone in the development of the Company’s development history. Looking ahead, we will expeditiously promote the commercialization of SM03, further expand the pipeline of drugs candidates, continue discovering and developing novel drugs for the treatment of immunological diseases by leveraging our R&D capabilities, expand production scale and strengthen global businesses, striving to contribute to global and Chinese biomedical innovation.”



*Dr. Shui On LEUNG, the Executive Director, Chairman of the Board and Chief Executive Officer of SinoMab BioScience Limited*



*Dr. Shui On LEUNG, the Executive Director, Chairman of the Board and Chief Executive Officer of SinoMab BioScience Limited (on the left) &*

*Mr. Jing QIANG, President of SinoMab BioScience Limited (On the right)*

*– End –*

### **About SinoMab BioScience Limited**

**SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK)** is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin's lymphoma, asthma, and other diseases with major unmet clinical needs.

This press release is issued by Porda Havas International Finance Communications Group for and on behalf of **SinoMab BioScience Limited**. For further information, please contact:

**Porda Havas International Finance Communications Group**

Ms. Angela Shi	+852 3150 6778	<a href="mailto:angela.shi@pordahavas.com">angela.shi@pordahavas.com</a>
Ms. Nicola Lung	+852 3150 6791	<a href="mailto:nicola.lung@pordahavas.com">nicola.lung@pordahavas.com</a>
Ms. Sarah Liang	+852 3150 6765	<a href="mailto:sarah.liang@pordahavas.com">sarah.liang@pordahavas.com</a>
Ms. Aimee Zhong	+852 3150 6769	<a href="mailto:aimee.zhong@pordahavas.com">aimee.zhong@pordahavas.com</a>